Clinical Trials Logo

Primary Biliary Cholangitis clinical trials

View clinical trials related to Primary Biliary Cholangitis.

Filter by:

NCT ID: NCT05239468 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Start date: March 21, 2022
Phase: Phase 2
Study type: Interventional

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

NCT ID: NCT05190523 Completed - Clinical trials for Primary Biliary Cholangitis

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Start date: April 6, 2022
Phase: Phase 2
Study type: Interventional

This study is a phase II, multicenter, randomized, double-blind, placebo-controlled, seamless adaptive design clinical study, aiming to evaluate the safety and effectiveness of three doses of ASC42 matched placebo in subjects with primary biliary cholangitis.

NCT ID: NCT05151809 Recruiting - Clinical trials for Primary Biliary Cholangitis

National Database on Primary Biliary Cholangitis

PBC322
Start date: September 19, 2019
Phase:
Study type: Observational [Patient Registry]

Primary biliary cholangitis (PBC) is a rare, autoimmune, cholestatic liver disease. No data about the disease epidemiology exist in Italy. Therefore this study aims to develop a national PBC patient database linked to a biological sample storage.

NCT ID: NCT05133336 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

EPICS-III
Start date: April 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)

NCT ID: NCT05104853 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Start date: January 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

NCT ID: NCT05050136 Recruiting - Clinical trials for Primary Biliary Cholangitis

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

VANTAGE
Start date: September 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.

NCT ID: NCT05014672 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

TRANSFORM
Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).

NCT ID: NCT04950764 Recruiting - Hepatic Impairment Clinical Trials

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Start date: September 17, 2021
Phase: Phase 1
Study type: Interventional

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT ID: NCT04650243 Recruiting - Clinical trials for Primary Biliary Cholangitis

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC

UCDA PBC
Start date: March 21, 2020
Phase: Phase 4
Study type: Interventional

This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.

NCT ID: NCT04620733 Completed - Clinical trials for Primary Biliary Cholangitis

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Start date: April 21, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo